tiprankstipranks
Advertisement
Advertisement

SNDX Stock Latest News

Syndax price target raised to $34 from $28 at Goldman Sachs
The FlySyndax price target raised to $34 from $28 at Goldman Sachs
14d ago
SNDX
Syndax price target lowered to $43 from $45 at Mizuho
PremiumThe Fly
Syndax price target lowered to $43 from $45 at Mizuho
14d ago
SNDX
Syndax assumed with a Buy at Jefferies
PremiumThe Fly
Syndax assumed with a Buy at Jefferies
15d ago
KURA
SNDX
Syndax price target raised to $45 from $33 at JPMorgan
PremiumThe Fly
Syndax price target raised to $45 from $33 at JPMorgan
1M ago
SNDX
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push
PremiumCompany Announcements
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push
1M ago
SNDX
Syndax price target raised to $57 from $51 at Citi
PremiumThe FlySyndax price target raised to $57 from $51 at Citi
1M ago
SNDX
Syndax reports Q4 EPS (78c), consensus (58c)
Premium
The Fly
Syndax reports Q4 EPS (78c), consensus (58c)
2M ago
SNDX
Syndax sees operating expense base remaining stable over next few years
Premium
The Fly
Syndax sees operating expense base remaining stable over next few years
2M ago
SNDX
SNDX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SNDX Upcoming Earnings Report: What to Expect?
2M ago
SNDX
Syndax price target raised to $28 from $27 at BofA
PremiumThe Fly
Syndax price target raised to $28 from $27 at BofA
2M ago
SNDX
Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next
PremiumCompany Announcements
Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next
3M ago
SNDX
Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
PremiumRatings
Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
3M ago
SNDX
Syndax: Strong Revuforj and Niktimvo Momentum Undervalues Commercial Trajectory and Pipeline Upside
PremiumRatingsSyndax: Strong Revuforj and Niktimvo Momentum Undervalues Commercial Trajectory and Pipeline Upside
3M ago
SNDX
Syndax Highlights Strong 2025 Results and Path to Profitability
Premium
Company Announcements
Syndax Highlights Strong 2025 Results and Path to Profitability
3M ago
8K
SNDX
Syndax announces expected milestones for 2026
Premium
The Fly
Syndax announces expected milestones for 2026
3M ago
SNDX
Syndax reports preliminary Q4 Revuforj revenue $44M
PremiumThe Fly
Syndax reports preliminary Q4 Revuforj revenue $44M
3M ago
SNDX
Syndax, WODA collaborate to launch program to expand access to Revuforj
PremiumThe Fly
Syndax, WODA collaborate to launch program to expand access to Revuforj
3M ago
SNDX
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
PremiumCompany Announcements
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
4M ago
8K
SNDX
Promising Growth Prospects for Syndax Pharmaceuticals: Buy Rating Affirmed by Analyst
PremiumRatings
Promising Growth Prospects for Syndax Pharmaceuticals: Buy Rating Affirmed by Analyst
4M ago
SNDX
Promising Potential of Syndax Pharmaceuticals’ Revuforj in AML Treatment Drives Buy Rating
PremiumRatingsPromising Potential of Syndax Pharmaceuticals’ Revuforj in AML Treatment Drives Buy Rating
4M ago
SNDX
Syndax price target raised to $35 from $22 at Barclays
Premium
The Fly
Syndax price target raised to $35 from $22 at Barclays
5M ago
SNDX
Syndax price target lowered to $33 from $40 at JPMorgan
Premium
The Fly
Syndax price target lowered to $33 from $40 at JPMorgan
5M ago
SNDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >